---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-335056"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2026-08-05T20:06:23+00:00"
generated_at: "2026-08-05T20:09:28.085659+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sarepta Q2 net product revenue $328.7M; GAAP operating income $13.3M; narrows FY2026 guidance

## Summary
- Net product revenue $328.7M: PMO $230.6M, ELEVIDYS $98.1M; total revenue $401.3M, down 34% YoY.
- GAAP net loss $4.9M ($0.05 diluted loss); non-GAAP net income $78.6M ($0.64 diluted EPS).
- Narrowed FY2026 net product revenue guidance to $1.2-$1.3B; non-GAAP R&D+SG&A to $800-$850M.
- Appointed Michael Severino, MD, as CEO effective July 28, 2026; Doug Ingram retired.
- Cash, equivalents, restricted cash and investments $945M, up ~$197M in the quarter.

## SEC filing metadata
- accession: 0001193125-26-335056
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2026-08-05T20:06:23+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000119312526335056/0001193125-26-335056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000119312526335056/srpt-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-335056
- JSON: https://secwatch.observer/filing/0001193125-26-335056.json
- Plain text: https://secwatch.observer/filing/0001193125-26-335056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.